A sealed and unbreached system for purification, stimulation, and expansion of cytomegalovirus-specific human CD4 and CD8 T lymphocytes

Transfusion

Volumn 46, Issue 12, 2006, Pages 2053-2062

  Li Pira, Giuseppina ^a   Bottone, Laura ^b   Ivaldi, Federico ^b   Pelizzoli, Roberta ^b   Risso, Marco ^b   Tripodi, Gino ^b   Manca, Fabrizio ^b  

^a ADVANCED BIOTECHNOLOGY CENTER   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ALLOIMMUNITY; ANTIGEN SPECIFICITY; ARTICLE; BIOSAFETY; BLOOD; BLOOD BANK; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL LINE; CELL PROLIFERATION; CELL SEPARATION; CELL STIMULATION; CELL TRANSFER; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; DEVICE; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; PURIFICATION; QUALITY CONTROL; SEALED CONTAINER; T LYMPHOCYTE;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL SEPARATION; CULTURE MEDIA; CYTOMEGALOVIRUS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION;

EID: 33751358592     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00977.x     Document Type: Article

References (41)

1. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;153:478-88.
2. Hibberd PL, Snydman DR. Cytomegalovirus infection in organ transplant recipients. Infect Dis Clin North Am 1995;9:863-77.
3. Kovacs JA, Masur H. Opportunistic infections. In: De Vita TJ, Rosenberg SA, editors. AIDS etiology, diagnosis, treatment and prevention. Philadelphia: Lippincott; 1992. p. 199-218.
4. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998;4:953-6.
5. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 1997;157:217-22.
6. O'Reilly RJ, Small TN, Papadopoulos E, et al. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997;157:195-216.
7. Polic B, Hengel H, Krmpotic A, et al. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 1998;188:1047-54.
8. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995;13:545-86.
9. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-41.
10. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-44.
11. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99:3916-22.
12. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003;362:1375-7.
13. Kern F, Surel IP, Brock C, et al. T-cell epitope mapping by flow cytometry. Nat Med 1998;4:975-8.
14. Reddehase MJ. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2002;2:831-44.
15. Sun Q, Burton RL, Dai LJ, et al. B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen. J Immunol 2000;165:4105-11.
16. Keever-Taylor CA, Margolis D, Konings S, et al. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells. Biol Blood Marrow Transplant 2001;7:247-56.
17. Andre-Schmutz I, Dal Cortivo L, Hamel Y, Cavazzana-Calvo M. Gene transfer for activation of CMV specific T cells. Hum Immunol 2004;65:565-70.
18. Kern F, Bunde T, Faulhaber N, et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis 2002;185:1709-16.
19. Nastke MD, Herrgen L, Walter S, et al. Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire. Cell Mol Life Sci 2005;62:77-86.
20. Li Pira G, Bottone L, Ivaldi F, et al. Identification of new Th peptides from the cytomegalovirus protein pp65 to design a peptide library for generation of CD4 T cell lines for cellular immunoreconstitution. Int Immunol 2004;16:635-42.
21. Li Pira G, Bottone L, Ivaldi F, et al. Generation of cytomegalovirus (CMV)-specific CD4 T cell lines devoid of alloreactivity, by use of a mixture of CMV-phosphoprotein 65 peptides for reconstitution of the T helper repertoire. J Infect Dis 2005;191:215-26.
22. Trivedi D, Williams RY, O'Reilly RJ, Koehne G. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood 2005;105:2793-801.
23. Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996;70:7569-79.
24. Diamond DJ, York J, Sun JY, et al. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997;90:1751-67.
25. Roden MM, Lee KH, Panelli MC, Marincola FM. A novel cytolysis assay using fluorescent labeling and quantitative fluorescent scanning technology. J Immunol Methods 1999;226:29-41.
26. Neri S, Mariani E, Meneghetti A, et al. Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol 2001;8:1131-5.
27. Kunkl A, Mortara L, Valle MT, et al. Recognition of antigenic clusters of Candida albicans by T lymphocytes from human immunodeficiency virus-infected persons. J Infect Dis 1998;178:488-96.
28. Manca F, Dessi V, Shastri N, et al. Isolation of lysozyme-specific T cell clones that discriminate between native and denatured antigen. Cell Immunol 1994;154:420-9.
29. Li Pira G, Oppezzi L, Seri M, et al. Repertoire breadth of human CD4+ T cells specific for HIV gp120 and p66 (primary antigens) or for PPD and tetanus toxoid (secondary antigens). Hum Immunol 1998;59:137-48.
30. Valle MT, Megiovanni AM, Merlo A, et al. Epitope focus, clonal composition and Th1 phenotype of the human CD4 response to the secretory mycobacterial antigen Ag85. Clin Exp Immunol 2001;123:226-32.
31. Li Pira G, Fenoglio D, Bottone L, et al. Preservation of clonal heterogeneity of the Pneumocystis carinii-specific CD4 T cell repertoire in HIV infected, asymptomatic individuals. Clin Exp Immunol 2002;128:155-62.
32. Levine BL, Bernstein WB, Aronson NE, et al. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 2002;8:47-53.
33. Manca F, Fenoglio D, Franchin E, et al. Anti-HIV genetic treatment of antigen-specific human CD4 lymphocytes for adoptive immunotherapy of opportunistic infections in AIDS. Gene Ther 1997;4:1216-24.
34. Palu G, Li Pira G, Gennari F, et al. Genetically modified immunocompetent cells in HIV infection. Gene Ther 2001;8:1593-600.
35. Sorg RV, Ozcan Z, Brefort T, et al. Clinical-scale generation of dendritic cells in a closed system. J Immunother 2003;26:374-83.
36. Muul LM, Nason-Burchenal K, Carter CS, et al. Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy. J Immunol Methods 1987;101:171-81.
37. Luhm J, Brand JM, Koritke P, et al. Large-scale generation of natural killer lymphocytes for clinical application. J Hematother Stem Cell Res 2002;11:651-7.
38. Li Pira G, Bottone L, Ivaldi F, et al. Recognition of CMV pp65 protein antigen by human CD4 T-cell lines induced with an immunodominant peptide pool. Hum Immunol 2004;65:537-43.
39. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005;202:379-86.
40. Hebart H, Bollinger C, Fisch P, et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 2002;100:4521-8.
41. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005;106:4397-406.